The SocietyMore than 35,000 clinicians, scientists and allied health professionals from over 160 countries are part of the ERS communityBecome an ERS member
The continued professional development (CPD) framework for thoracic oncology is broken down into modules. This framework supports structured learning for respiratory professionals and allows them to navigate the related learning activities and events offered by ERS.
Basic principles of carcinogenesis, including the dysplastic lesion-carcinoma in situ-invasive lesion sequence
Tumour immunology
Basic principles related to tumour immunology, including the general structure of innate and adaptive immune recognition and immune responses in humans as well as the elimination-equilibrium-escape sequence
Current epidemiology of active and passive smoking, heated tobacco products and smokeless tobacco products as well as other smoked or vape-related products worldwide and nationally in relation to thoracic malignancies
Pathogenic mechanisms of active and passive smoking, heated tobacco products and smokeless tobacco products related to thoracic malignancies
Socio-economic and cultural aspects of tobacco consumption related to thoracic malignancies
Indications, contraindications, limitations and benefit-risk assessment as well as quality aspects for diagnostic flexible and rigid bronchoscopy and diagnostic techniques in the context of thoracic oncology
Indications, contraindications, limitations and benefit-risk assessment as well as quality aspects for therapeutic bronchoscopy in the context of thoracic oncology (stents, cryotherapy, laser techniques, argon plasma, brachytherapy, electrocautery and photodynamic therapy)
Principles of discontinuation and bridging of anticoagulants
Indications, contraindications, limitations and benefit-risk assessment as well as quality aspects for each procedure (including EBUS/EUS) in the context of thoracic oncology
Different ranges of the methods
Basic lymph node anatomy/stations of the mediastinum
Principles of discontinuation and bridging of anticoagulants
Indications, contraindications, limitations and benefit-risk assessment as well as quality aspects for diagnostic thoracoscopy in the context of thoracic oncology
Indications, contraindications, limitations and benefit-risk assessment as well as quality aspects for therapeutic thoracoscopy in the context of thoracic oncology (talc pleurodesis)
Principles of discontinuation and bridging of anticoagulants
Basic principles of diagnostic steps in pathology related to thoracic malignancies
light microscopy: Small cell carcinoma (SCC) vs non small cell carcinoma (NSCLC), squamous vs non-squamous carcinoma, carcinoids
role of immunohistochemistry
molecular pathology: actionable mutations (EGFR, BRAF, MET, NTRK1, Her 2) and gene rearrangements (ALK, ROS1, RET), resistance mutations
Basic principles of proper handling of samples in suspected thoracic malignancies
Tissue preservation and quality of samples (adequate tumour contents) for light microscopy, immunohistochemistry and molecular pathology (DNA and RNA studies)
Effects of smoking, heated tobacco products and smokeless tobacco products as well as other smoked or vape-related products on the health of the individual in relation to thoracic oncology
Beneficial effects of smoking cessation for preventing thoracic malignancies as well as during and after treatment of thoracic malignancies
Indications, contraindications, limitations and benefit-risk assessment as well as quality aspects for thoracentesis including a chest tube and a tunnelled indwelling pleural catheter
Principles of discontinuation and bridging of anticoagulants
Basic principles of diagnostic (recommended procedures and histopathology) and therapeutic management of malignant pleural mesothelioma including multi-modal treatment modalities
Metastatic pulmonary tumours as a differential diagnosis of pulmonary nodules/masses (e.g. pulmonary metastasis in thyroid, colorectal, prostate, renal or mammary gland carcinoma as well as soft tissue sarcoma and osteogenic sarcoma)
TERAVOLT is a global consortium dedicated to the treatment of patients with thoracic malignancies who have come together to understand the impact of COVID-19 on cancer patients.
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies. However you may visit Cookie Settings to provide a controlled consent.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.